NCT05533632

Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

Safety and Tolerability of Weekly Semaglutide 0.5 mg or 1.0 mg in Chilean Subjects With Type 2 Diabetes

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 104 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is testing the safety and tolerability of subcutaneous semaglutide in participants with type 2 diabetes (T2D) in Chile. Participants will get a once-weekly subcutaneous injection of semaglutide in doses decided by the study doctor's criteria, according to participant's personal needs. The study will last for about 24 weeks. Participants will have 4 clinic visits and 2 phone calls. Participants will have 3 laboratory tests during the study (blood and urine samples).

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	Semaglutide	Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.

Timeline

• Start date: 2022-04-25
• Primary completion: 2024-01-18
• Completion: 2024-01-18
• First posted: 2022-09-09
• Last updated: 2025-09-24
• Results posted: 2025-02-10

Locations

3 sites across 1 country: Chile